← News
2025 Psychedelics
Sub-Psychedelic Doses of 5-MeO-DMT Passed a Phase 1 Safety Check
A placebo-controlled Phase 1 trial gave 36 adults with depression or anxiety weekly sublingual microdoses of 5-MeO-DMT — 6, 9, or 12mg — for four weeks. No serious adverse events, no organ toxicity, and no one reported an actual psychedelic effect at these doses. It's a safety study, not an efficacy one, but it's the groundwork any microdosing claim about this compound needs before it means anything clinically.
Read at Neuropsychopharmacology